In this experiment, it is expected that PD-L1 expressed by spheroid cells will interact with PD-1 expressed by activated cytotoxic cells, reducing their killing capabilities, and that nivolumab and pembrolizumab anti-PD-1 antibodies will block PD-1-PD-L1 interaction and increase tumor cell destruction. This evidence concerns the gene CD274 and neoplasm.